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Abstract
Background: There is limited research on the economic burden of low back-related leg pain, including sciatica.
The aim of this study was to describe healthcare resource utilisation and factors associated with cost and health
outcomes in primary care patients consulting with symptoms of low back-related leg pain including sciatica.
Methods: This study is a prospective cohort of 609 adults visiting their family doctor with low back-related leg
pain, with or without sciatica in a United Kingdom (UK) Setting. Participants completed questionnaires, underwent
clinical assessments, received an MRI scan, and were followed-up for 12-months. The economic analysis outcome
was the quality-adjusted life year (QALY) calculated from the EQ-5D-3 L data obtained at baseline, 4 and 12-months.
Costs were measured based on patient self-reported information on resource use due to back-related leg pain and
results are presented from a UK National Health Service (NHS) and Societal perspective. Factors associated with
costs and outcomes were obtained using a generalised linear model.
Results: Base-case results showed improved health outcomes over 12-months for the whole cohort and slightly
higher QALYs for patients in the sciatica group. NHS resource use was highest for physiotherapy and GP visits, and
work-related productivity loss highest from a societal perspective. The sciatica group was associated with
significantly higher work-related productivity costs. Cost was significantly associated with factors such as self-rated
general health and care received as part of the study, while quality of life was significantly predicted by self-rated
general health, and pain intensity, depression, and disability scores.
Conclusions: Our results contribute to understanding the economics of low back- related leg pain and sciatica and
may provide guidance for future actions on cost reduction and health care improvement strategies.
Trial registration: 13/09/2011 Retrospectively registered; ISRCTN62880786.
Keywords: Cost, Outcome, Back pain, Leg pain, And sciatica
Background
Low back pain (LBP) is a common health condition
worldwide [1] and poses a significant burden on individ-
uals’ quality of life [2]. In primary care, 60% of patients
presenting with LBP also report leg pain, a proportion of
those patients will have sciatic pain [3]. The presence of
both, low back-related leg pain and sciatica is linked
with increased pain, disability, poorer health outcomes,
and work absence, compared to LBP without symptoms
in the leg(s) [4], and consequently contributes signifi-
cantly to the economic burden on individuals and
society in general. Patients with low back-related leg
pain not attributed to sciatica are labelled as having
‘referred’ (non-specific) leg pain, we will use this term
when we describe this group.
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The economic burden of LBP has been investigated
comprehensively, and found to be substantial [5, 6]. To
date, there is limited research on the economic burden
of low back-related leg pain, including sciatica. A previ-
ous Dutch study estimated societal sciatica costs of
about 13% of overall LBP related costs, equivalent to a
current annual impact on the United Kingdom (UK)
economy of over £500 million in healthcare costs and
£3.8 billion in indirect costs related to sciatica [7, 8].
Given the socioeconomic impact of sciatica, a number of
trials have investigated the effectiveness of available
treatments, from medications to surgery [9–11], and
national and international guidelines recommend timely
assessment of patients presenting with sciatica in pri-
mary care [12, 13]. There is however limited research on
the determinants of quality of life and cost outcomes in
LBP patients, and specifically few studies have investi-
gated patients presenting with sciatica or with referred
leg pain, in the primary care setting. A prospective
description of costs and quality of life outcomes of this
patient group will improve understanding of healthcare
determinants, societal costs and health outcomes, and
inform health care policy and planning.
The objective of this study is to provide data on the
distribution of healthcare usage, costs and quality of life
outcomes in primary care patients consulting with low
back-related leg pain according to the presence/absence
of sciatica, and explores factors associated with costs
and quality of life outcomes for patients with symptoms
of low back-related leg pain including sciatica.
Methods
Cohort study design and population
Full details of this prospective cohort study are pub-
lished in the ATLAS (Assessment and Treatment of Leg
pain Associated with the Spine) study protocol [14], and
results papers [15, 16]. The study’s aims and methods
are briefly described here. Ethical Approval for this study
was obtained from the South Birmingham Research
Ethics Committee (REC ref. 10/H1207/82). The primary
objective of the ATLAS study was to investigate overall
prognosis of patients seeking care for symptoms of low
back-related leg pain, including sciatica. The study popula-
tion consisted of 609 adults aged 18 years and over with
symptoms of low back-related leg pain, including sciatica,
of any severity and duration, recruited from the National
Health Service (NHS) general practices in North Stafford-
shire and Stoke-on-Trent. Patient recruitment was carried
out between April 2011 and March 2013. Adults, visiting
their General Practitioner (GP) with low back-related leg
pain including sciatica, of any duration and intensity, who
met pre-set study criteria, were invited to participate. At a
research clinic, all study patients after giving written in-
formed consent were assessed by a physiotherapist to
confirm eligibility [15, 16]. Patients also received a mag-
netic resonance imaging (MRI) scan (within 10 working
days) as part of the research study, providing there were
no contraindications to the procedure. Patients were
clinically diagnosed as having sciatica or referred (non-
specific) leg pain based on the examiner’s clinical opinion.
Participation in the study did not infer any particular
treatment advantage for the participants, treatments and
treatment pathways were based on best clinical practice.
In terms of care pathways, most patients received a course
of physiotherapy, a small number of patients were referred
to a specialist spinal service for consideration of spinal in-
jections and/or surgery, and a small number of patients
proceeded to have these procedures.
Overview of economic analysis
An economic regression-based analysis of costs and
quality of life outcomes was conducted alongside the
observational cohort study. The economic analysis used
costs and QALYs as the main outcomes, with the ana-
lysis conducted from an NHS and societal perspective
and designed to capture data at 4 and 12 months. The
main focus of the analysis was to investigate the distri-
bution of resource use and quality of life outcomes in
these patients with referred leg pain or sciatica, and the
predictors of costs and quality of life outcomes in the
whole cohort, with a secondary analysis focusing on the
subgroup clinically diagnosed with sciatica.
Quality of life outcome data
Preference-based health outcome data were collected at
baseline, 4 and 12months follow-up, using the patient
completed EQ-5D-3 L questionnaire. The EQ-5D-3 L is a
generic instrument measuring and valuing health related
quality of life [17]. Responses from individuals were con-
verted to utility values obtained using the UK value set
derived from a UK general population survey [18] and
expressed in QALYs using the area-under-the-curve ap-
proach linking utility scores at various time-points [19]. Ad-
justment for differences between patients with or without
sciatica in baseline EQ-5D-3 L scores was performed using
a regression-based adjustment in order to avoid bias [20].
Other secondary outcomes were also collected using self-
completed questionnaires [21–27] (see Additional file 1).
Resource use and cost data
Resource-use data due to low back-related leg pain/sciat-
ica were collected from participants at 4 and 12months
from the time of recruitment into the study, using self-
report postal questionnaires. The questionnaires specific-
ally requested information on low back-related leg pain/
sciatica healthcare resource utilisation including primary
care consultations (e.g. GP, practice nurse, physiotherap-
ist), prescribed medication, over-the-counter treatments
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and secondary care attendances including healthcare pro-
fessionals (e.g. hospital consultants and physiotherapists),
investigations (e.g. e.g. X-rays, MRI scans), and procedures
such as surgery (injections, surgeries). Self-reported work-
related data on time-off work were also collected in order
to assess the impact of indirect costs of sickness absence
due to low back related leg pain. Details of the number of
study-related physiotherapy sessions attended by each
participant were collected as part of the study through
case report forms and costed separately from other
physiotherapy visits. Study protocol-driven MRI scan costs
were excluded from the analysis as these would not neces-
sarily occur in usual practice.
Total 12-month costs per person were estimated by
combining resource use data with unit costs. Unit
costs were obtained from the British National Formu-
lary (BNF) [28] for drugs, and the NHS Reference
costs [29] and Unit Costs of Health and Social Care
[30] for other resource use items (see Additional file 2)
. Productivity costs were estimated using the human
capital approach (wage cost per day multiplied by the
number of absence days), salary costs were based on
respondent job-specific wage estimates identified from
annual earnings data and UK Standard Occupational
Classification coding [31–33]. Out-of-pocket treatment
costs were based on patient reported costs. All costs
were expressed in 2013/2014 UK (£) prices.
Data analysis
An analysis of costs and quality of life outcomes was
conducted to determine the difference in costs and
QALYs over a 12-month period between the group of
patients with sciatica and those with referred leg pain.
Multiple-imputation using chained equations was used
to impute missing values for costs and EQ-5D-3 L scores
for non-responders to the 4 and 12-month question-
naires [34]. Confidence intervals for the mean differ-
ences in resource use and costs were obtained by bias
corrected and accelerated non-parametric bootstrapping,
using 1000 replications [35]. Discounting was not per-
formed because of the 12month follow-up period. De-
scriptive statistics (mean, standard deviation) and 95%
confidence intervals for resource use, costs and QALYs
are presented for the whole cohort and separately for
the sciatica and referred leg pain groups.
Separate GLMs with log link and gamma variance
functions were fitted for the whole cohort, to identify
factors that influence total costs and QALYs [36]. GLM
models account for non-normality in the outcome
variables. Factors to be examined were selected a-priori
based on evidence of their association with costs and
health-related quality of life outcomes, building on
evidence from previous studies, and expertise within the
study team (Additional file 1). GLMs were used to
examine the relationship of each factor with the cost
(NHS and societal) and QALYs. Factors with p < 0.25
were carried forward to the multivariable model for
each cost and quality of life outcome variables. The
final models reported significance at p < 0.01, p < 0.05
and p < 0.1. All statistical analyses were performed
using Stata V.13 analysis software [37]. The base-case
analysis was from a UK NHS perspective, using the
imputed cost and QALY dataset while adjusting for
baseline EQ-5D-3 L scores and a secondary analysis
from a societal perspective. As part of sensitivity ana-
lysis, separate models were fitted to identify predictive
cost and outcome factors for the sciatica group only.
Results
A total of 609 participants ((sciatica (n = 452), referred
leg pain (n = 157)) formed the dataset for the analysis.
The mean age of participants was 50, with over half of
the respondent’s female (62%); 32% were smokers and
just over 13% had two or more other health problems.
At baseline, 61 and 59% of respondents were in paid
employment in the sciatica and referred leg pain group.
An additional file describes the participant’s characteris-
tics at baseline in more detail (see Additional file 3). All
base-case analyses reflect the imputed dataset unless
otherwise stated.
Health-related quality of life outcomes
Mean EQ-5D-3 L scores at baseline and follow-up time-
points and mean QALYs are shown in Table 1. The
distribution of quality of life outcomes was similar for the
overall cohort and the sciatica and referred leg pain
groups. Health-related quality of life improved over time
in the whole cohort and in the two groups. The un-
adjusted and imputed mean QALYs over 12months were
marginally higher among the referred leg pain compared
to the sciatica group. This result changed in favour of the
sciatica group after adjusting for baseline differences.
Resource use and costs
Table 2 shows the disaggregated details of mean resource
use for participants with complete resource use data.
Overall, the whole cohort analysis showed that health care
resource use was highest for GP consultations, outpatient
consultations, medication and physiotherapy visits not
related to the study. Similar findings were observed in the
two groups, with the sciatica group being associated with
more GP visits, investigations (MRIs and X-rays not re-
lated to the study protocol) and prescribed medications
(Table 2). Over the 12-month period, the mean (SD) total
NHS cost for all patients in the cohort was £296.56
(326.75) (Table 3). NHS costs were highest for non-study
related physiotherapy visits, outpatient consultation, GP
consultations and investigations.
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The mean (SD) total societal cost for all patients in
the cohort was £1106.14 (2328.54) (Table 3). The largest
proportion (65%) of costs incurred by society was from
indirect costs (lost productivity) due to the symptoms of
low back and leg pain, with overall total costs for the
whole cohort amounting to £728.14 (2635.13). Only 26%
of the societal cost was incurred by the NHS.
Over the period of 12 months, there were observed
differences in uptake of primary care and hospital visits
and visits to ‘other’ professionals, and societal costs
Table 1 Mean (SD) health-related quality of life outcomes per patient over 12 months
EQ-5D-3 L scores ALL Referred leg pain Sciatica
Base case (Imputed) analysis n = 609 n = 157 s = 452
Baseline 0.446 (0.316) 0.470 (0.306) 0.438 (0.320)
4 months 0.625 (0.266) 0.644 (0.237) 0.613 (0.275)
12 months 0.663 (0.243) 0.649 (0.232) 0.669 (0.246)
Total 12 month QALYs
Unadjusted 0.608 (0.228) 0.617 (0.214) 0.606 (0.232)
Difference (Bootstrapped 95% CI’s) −0.011 (− 0.049 to 0.031)
Adjusteda 0.608 0.605 0.610
Difference (Bootstrapped 95% CI’s) 0.005 (−0.021 to 0.032)
aThe values are predicted mean scores obtained from the multiple regression equation when controlling for baseline imbalances
QALY quality-adjusted life years, CI confidence intervals
Table 2 Health care resource use over 12 months (mean, SD)
Resource use
Variable ALL Referred leg pain Sciatica
n = 368 n % n = 85 n % n = 283
ATLAS physiotherapya 3.38 (2.34) 2.80 (2.08) 3.56 (2.39)
NHS
GP consultations 2.12 (3.17) 42 (49) 1.48 (2.59) 161 (56) 2.31 (3.29)
Nurse consultations 0.14 (0.60) 10 (12) 0.22 (0.81) 18 (7) 0.11 (0.53)
Other primary care consultations 0.81 (2.36) 15 (18) 0.93 (2.95) 52 (19) 0.77 (2.16)
Outpatient consultationsb 3.15 (4.78) 40 (47) 2.73 (4.26) 160 (56) 3.28 (4.93)
‘Other’ physiotherapyd 2.48 (3.90) 35 (42) 2.13 (3.35) 130 (46) 2.59 (4.06)
Consultations otherb 0.07 (0.35) 3 (7) 0.07 (0.26) 6 (4) 0.07 (0.37)
Private
Outpatient consultationsb 1.18 (4.96) 8 (10) 1.82 (7.62) 40 (15) 0.99 (3.82)
‘Other’ Physiotherapyd consultations 0.44 (2.19) 4 (5) 0.47 (2.77) 21 (7) 0.43 (1.99)
Consultations otherb 0.05 (0.41) 0 0.00 5 (3) 0.07 (0.46)
Time off work
(Days off work)
8.92 (30.71) 13 (16) 3.08 (11.55) 66 (24) 10.67 (34.25)
n (%) n (%) n (%)
Investigationsc
(MRI)
13 (4) 1 (1) 12 (4)
Investigationsc
(X-rays)
26 (7) 7 (8) 19 (7)
Prescribed medicationc 105 (29) 18 (21) 87 (31)
Over the counterc medications 94 (26) 24 (28) 70 (25)
NHS National Health Service costs, MRI Magnetic resonance imaging
a
Physiotherapy treatment sessions received as part of the study
b
Hospital based or private practice based consultations
c
The number (%) of participants reporting usage within the investigations, prescribed medication and out-of-pocket and prescribed categories are reported instead of mean (SD) because of multiple usage,
purchases and/or prescriptions
d
Physiotherapy visits over and above those that were delivered as part of the ATLAS study
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between the two groups with the sciatica group being
associated with more GP visits, investigations, prescribed
medication and visits to hospital consultants and other
health professionals. The mean NHS costs per patient
were £313 for the sciatica group compared with £250 for
referred leg pain group. During the 12- month follow-
up, the mean number of days off work was higher in the
sciatica group (10.7 days) than in the referred leg pain
group (3.1 days). This translated into higher productivity
costs in the sciatica group (£882) compared to the
referred leg pain group (£216), this difference was statis-
tically significant. Table 3 shows the disaggregated mean
(SD) NHS and societal costs per patient for each group
and total cost estimates for the imputed data analysis.
Impact of patient characteristics on cost and quality of
life
Tables 4 to 5 show regression coefficients (95% CIs) for
each of the potential predictors of cost and quality of
life, representing the additional change associated with
one-unit changes in each of these factors. From an NHS
perspective, the final model included only three of the
pre-selected variables (p < 0.25), none of which had a sta-
tistically significant impact on healthcare costs (Table 4).
However, it can be observed from the societal costs final
model including five of the pre-selected variables (Table 4),
that the care pathway in the ATLAS study which was de-
fined as a course of physiotherapy of 3 or more sessions,
and better general health scores, were significantly associ-
ated with reduced costs (p = 0.024 and p = 0.063 respect-
ively). The quality of life final regression model included
all pre-selected variables, seven of which were significantly
associated with poor quality of life (p < 0.05), these were:
poorer self-reported general health, higher low back or leg
pain intensity, higher depression score, higher disability
score, patient’s belief/perception that their symptoms will
be long-lasting, gender, and the ATLAS care pathway
defined as a referral to spinal specialist services (Table 5).
Sensitivity analysis
The results of the model analyses for costs and quality
of life in the sciatica subgroup analyses were in line with
base-case (whole cohort) findings. The exception in the
analysis of quality of life was that the disability and care
Table 3 Mean (SD) costs per patient over 12 months
Cost (£)
ALL Referred leg pain Sciatica Mean difference (95% CI)
ATLAS physiotherapy 43.09 (24.42) 36.94 (22.46) 44.94 (24.72)
n = 368 n = 85 n = 283
Primary care
GP consultations 72.07 (107.65) 50.40 (88.35) 78.57 (112.12) 28.17 (2.84 to 49.48)
Practice nurse consultations 1.25 (5.44) 2.01 (7.26) 1.02 (4.74) −0.99 (−2.74 to 0.39)
Consultations with other professionals 5.86 (16.32) 5.18 (15.79) 6.06 (16.49) 0.88 (−3.09 to 4.76)
Prescriptions 1.02 (1.65) 0.65 (1.15) 1.13 (1.76) 0.33 (−3.19 to 3.20)
Hospital-based care
NHS professional visits 59.08 (169.59) 51.64 (206.40) 61.32 (157.22) 9.68 (−40.87 to 51.47)
Private professional visits 33.61 (177.62) 59.61 (274.68) 25.80 (135.34) −33.81 (−98.19 to 19.68)
Investigations (MRI, X-rays) 35.97 (93.57) 34.03 (108.76) 36.55 (88.71) 2.52 (−29.54 to 23.75)
Other healthcare professionals
Additional NHS physiotherapy 109.28 (172.03) 93.69 (147.62) 113.96 (178.67) 20.27 (−20.69 to 55.45)
Private physiotherapy 19.37 (96.43) 20.71 (121.94) 18.97 (87.58) −1.74 (−31.85 to 19.05)
NHS ‘other’ 1.76 (20.08) 3.2 (29.50) 1.32 (16.26) −1.87 (−10.67 to 2.62)
Private ‘other’ 0.99 (12.83) 0 1.29 (14.62) 1.29 (0.15 to 3.75)
Over the counter purchases 10.51 (24.29) 11.34 (30.83) 10.26 (22.02) −1.08 (−9.09 to 5.25)
Work-related: Time-off work associated with condition 728.14 (2635.13) 216.05 (857.31) 881.94 (2952.15) 665.89 (349.61 to 1120.31)
Imputed Analysis n = 157 n = 452
NHS costs 296.56 (326.75) 249.70 (301.58) 312.85 (333.83)
mean difference (95% CI) 63.14 (8.70 to 117.35)
Societal costs 1106.13 (2328.54) 700.82 (1006.76) 1246.92 (2623.35)
mean difference (95% CI) 546.11 (274.16 to 844.01)
NHS National Health Service costs, MRI Magnetic resonance imaging, C0049 Confidence interval
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pathway variables were no longer significant for the sci-
atica group (See Additional files 4 and 5). Similar results
were also observed in the regression analyses based on
the complete-case analysis (See Additional files 6 and 7).
Discussion
In this paper we report the total costs and quality of life
outcomes of primary care patients seeking care for
symptoms of back-related leg pain including sciatica,
and we describe the factors associated with costs and
quality of life outcomes in this patient group. To our
knowledge, this the first study to provide information on
costs (NHS and broader societal costs) and quality of life
health outcomes, and on factors associated with these,
in this population.
Our results from the overall cohort analyses demon-
strate that healthcare utilisation from the NHS perspec-
tive is highest for health professional consultations such
as physiotherapy and GPs. From a societal perspective,
costs were highest for work-related productivity loss (for
those in work). Similar findings were observed in the
analyses for the sciatica and referred leg pain groups. An
increase in the number of physiotherapy sessions (as
part of the ATLAS study) and higher self-reported
general health scores were significantly associated with
reduced resource utilisation and costs at 12 months
(approximately £1.5 and £1.2 respectively). The baseline
factors associated with improvement of quality of life in
this cohort were: higher scores of self-rated general
health, lower pain intensity, lower depression scores, and
Table 4 Factors associated with costs at 12 months, based on a
generalised linear model for the whole group
Coefficient (SE) n = 608
NHS Cost
Constant 5.95 (0.163) **
General Health
SF-1 general health −0.051 (0.055)
RMDQ −0.000 (0.009)
Psychological measures and perceptions
HADs depression −0.016 (0.014)
AIC: 13.39 BIC: − 3303.19
Societal Costs
Constant 8.12 (0.403) **
General Health
SF-1 general health −0.173 (0.099)*
RMDQ −0.009 (0.018)
Psychological measures and perceptions




Care pathways-unadjusted (0–2 physiotherapy sessions)
3 or more physiotherapy sessions −0.307 (0.160)*
Referrals to spinal specialist services −0.174 (0.256)
AIC:16.00 BIC:-2441.59
NHS National Health Service, RMDQ Roland Morris Disability Questionnaire, SE
Standard Error, HADs Hospital and Anxiety Depression scale
**p < 0.05,*p < 0.1
aSex is measured as 1 Female 0 Male
bComorbidities included none, one, 2 or more chest problems, heart problems,
raised BP, diabetes, circulation problems in leg(s)
Table 5 Generalised linear model with total QALYs at 12
months for the whole group
Coefficient (SE) n = 557
Constant 0.577 (0.140)**
General Health
SF-1 general health −0.079 (0.019)***
RMDQ −0.008 (0.004)**
Pain variables
Duration of current episode of leg pain (< 6 weeks)
6–12 weeks −0.014 (0.041)
Over 3 months −0.049 (0.037)
Pain intensity– highest of leg or back pain −0.066 (0.012)***
Psychological measures and perceptions
Illness perception:
Identityd −0.006 (0.013)
Timeline acutea (Strongly disagree/disagree/neither)
Agree/strongly agree −0.079 (0.032)**
HADs depression −0.022 (0.004)***
Personal characteristics
Age −0.002 (0.001)
Sex (Female)b 0.067 (0.032)**
BMI −0.003 (0.002)
Comorbiditiesc −0.038 (0.036)
Care pathways-unadjusted (0–2 physiotherapy sessions)
3 or more physiotherapy sessions 0.004 (0.032)
Referrals to specialist spinal services −0.119 (0.051)**
AIC: 0.99 BIC: − 3333.46
RMDQ Roland Morris Disability Questionnaire, SE Standard Error, HADs Hospital
and Anxiety Depression scale
***p < 0.01, **p < 0.05
aTimeline; illness/condition duration: ‘my back and / or leg problem will last
for a long time’). Timeline is measured on a Likert scale; strongly disagree -
Disagree - Neither agree or disagree - Agree - Strongly agree. For the purposes
of the analysis it was dichotomised ((agree (agree, strongly agree) versus
disagree (strongly disagree, disagree, neither agree nor disagree))
bSex is measured as 1 Female 0 Male
cComorbidities included none, one, 2 or more chest problems, heart problems,
raised BP, diabetes, circulation problems in leg(s)
dIdentity; Symptom attribution to the condition from a list of 7 potential
symptoms: back pain, leg pain, unable to sit comfortably, fatigue, stiff joints,
sleep difficulties, loss of strength. The score is the sum of symptoms
experienced The list of the 7 potential symptoms was chosen by the
research team
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lower disability scores. However, the disability score was
not a significant predictor of quality of life in the sciatica
group. A further finding was a higher number of days
off work in the sciatica group within the 12months
follow-up, resulting in higher societal costs.
LBP national and international guidelines have recom-
mended early assessment, diagnosis and management of
back-related leg pain in patients presenting with back-
related problems, with the view to prioritise timely and
appropriate management [12, 38]. However, information
on how costs and health related quality of life outcomes
vary between patients with sciatica and referred leg pain
remains limited, and patterns of how costs and outcomes
change over time, have not been explored. No previous
studies have assessed the impact of patient demographic
and clinical characteristics on the costs and quality of life
outcomes for this primary care population.
We did not find any significant association between
costs and age, gender, body mass Index, comorbidities,
disability, pain intensity, and depression in our sample.
This contrasts with more general literature which sug-
gests that costs of musculoskeletal conditions are often
associated with demographic factors such as age, and
disease specific factors such as depression and disability
[39–43]. Factors significantly associated with quality of
life outcomes in this cohort included general health,
disability, pain intensity, and depression.
The strengths of our study lie in the analysis ap-
proaches used, presentation of disaggregated results and
comprehensive assessment of factors associated with
costs and quality of life in patients consulting with
symptoms of low back-related leg pain including sciatica.
The analyses are also performed from a broader societal
perspective, and therefore report important work-related
outcomes that are particularly relevant for this patient
group, as most are of a working age. The analysis
considers a comprehensive set of potential prognostic
factors influencing cost and quality of life, underpinned
by previous research and clinical experience. However,
there are limitations to our analysis. Resource use infor-
mation was collected using self-reported data from study
participants at 4 and 12 months questionnaires. A limita-
tion of using self-report data only, is that it is subject to
recall and information bias (e.g patients not able to dis-
tinguish between LBP-related resource use and others)
and therefore respondents could potentially over-report
or under-report resource utilisation, particularly over
longer periods of recall [44]. Nevertheless self-reported
data provide an efficient means of obtaining economic
evaluation data in the absence of routine data sources
and has been widely used in similar studies [45–47].
Response rates for the main cost (60% at 12 months)
and EQ-5D 3 L outcome data (97% at baseline, 64% at 4
months and 68% at 12 months) were low raising some
concerns about the validity of the findings. However,
appropriate and robust multiple imputation approaches
were used to address potential biases resulting from in-
complete data. In addition, data for the ATLAS study
clinic sessions (which was significantly associated with
total costs) was observed from routine physiotherapy
databases, and could have influenced the overall results
of the model. Lastly, although we evaluated costs from a
societal perspective, we were not able to include all com-
ponents of the indirect costs. Our study therefore pre-
sents conservative estimates of the total societal costs
since presenteeism related costs were not included in
the cost analysis. These costs have been shown to be
greater than absenteeism in some cases [48].
The analysis reported here presents important infor-
mation on costs for treating patients with back-related
leg pain including sciatica. Within the ATLAS cohort,
patients with sciatica pain and referred leg pain appeared
to be similar in terms of quality-of-life outcomes
although patients in the sciatica group had a higher pro-
portion of consultation visits, medication and time-off
work. The productivity costs incurred by individuals in
this cohort as a result of back-related leg pain were
substantial. Therefore it is important that the cost-
effectiveness of interventions used for patients with low
back-related leg pain and sciatica, are investigated from
a perspective of both, the health provider and society.
The regression analyses showed that patient self-rated
general health and the number of physiotherapy sessions
received (as part of the ATLAS study) were important
predictors of resource utilisation and costs, possibly
indicating that initial comprehensive treatment seems to
reduce future need for health care use and costs. How-
ever, the study’s observational design precludes any
causal inferences. Baseline low levels of disability, pain
intensity and depression were associated with changes in
quality of life as measured by the EQ-5D-3 L. The
generalizability of the findings in this research is sup-
ported by the inclusion of eligible patients with any level
of intensity and duration of pain, as this broadens the
population beyond patients presenting with only the
most severe symptoms.
Conclusion
In conclusion, in 1 year, resource utilisation for primary
care patients with low back-related leg pain and sciatica
showed that health care and societal costs were highest
for visits to physiotherapists and GPs and in relation to
work-related productivity loss. Health-related quality of
life was low at baseline for the overall cohort and for
both the sciatica and referred leg pain groups, but im-
proved across all time points. The type of care received
and patient self-reported general health were important
variables for predicting future costs. Similarly to other
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musculoskeletal conditions, quality of life was signifi-
cantly influenced by characteristics such as levels of
disability, depression and pain intensity. Our study
contributes to understanding the economics of low
back-related leg pain and sciatica care and has important
implications for health care policy resource allocation in
this patient group.
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